Correlation of biochemical markers and clinical signs of hyperandrogenism in women with polycystic ovary syndrome (PCOS) and women with non-classic congenital adrenal hyperplasia (NCAH)
Strategies to enhance the tolerability of GLP-1-based therapy might include identification of agents that stimulate release of endogenous GLP-1 from intestinal L-cells, potentially accompanied by fewer adverse effects
Thus, NRF2 limits HSC activation and attenuates fibrosis progression by inhibiting the expression of these fibrogenic mediators [126] (Figure 2)
So obviously what youve tried hasnt worked, so theyre trying something different. Your prep for the appointment is refreshingly simple, though
GLP-1 medications work most effectively when paired with balanced eating, regular exercise, and professional guidance
Understanding the cardiovascular profile of GLP-1 agonists is essential for both prescribers and patients, particularly given the metabolic conditions they are used to treat often carry inherent cardiovascular risk
